Lin Xiaoying, Shao Tiejuan, Huang Lin, Wen Xianghui, Wang Mingzhu, Wen Chengping, He Zhixing
College of Basic Medical Science, Institute of Basic Research in Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Front Pharmacol. 2020 Jun 24;11:955. doi: 10.3389/fphar.2020.00955. eCollection 2020.
Simiao decoction, a classical traditional Chinese medicine (TCM) formula, has been widely used for thousands of years due to its safety and efficiency in treating gouty arthritis. Utilizing serum proinflammatory cytokines and gut ecosystems, this study elucidated the mechanisms of alleviating gouty arthritis by Simiao decoction. Simiao decoction (4.0, 8.0, and 16.0 g/kg) was orally administered to gouty arthritis mice and febuxostat was given as a positive control. The spleen, kidney, and liver indexes indicated that Simiao decoction was safe for the treatment of gouty arthritis in C57BL/6 mice. Besides, our study demonstrated that Simiao decoction was effective for reducing the level of serum uric acid and decreasing MPO, XOD, and ADA activity, as well as alleviating gouty-related symptoms, such as foot swelling and pain. Moreover, Simiao decoction could also reduce some specific serum proinflammatory cytokines including IL-1β, IL-9, IFN-γ, MIP-1α and MIP-1β. We then surveyed the effects of Simiao decoction on the gut ecosystems in a systematic manner by combining network pharmacology, ELISA, western blot, and illumina sequencing. In the murine of model of gouty arthritis, Simiao decoction could suppress NLRP3 inflammasomes expression, reduce gut apoptosis through modulating TNF-α, Caspase 8, and AIFM1 protein expressions, affect lipid metabolism by regulating APOB, LPL, PPARα protein expressions and restore gut microbiota reducing potential pathogens. Overall, these findings suggested that Simiao decoction was an effective therapeutic drug for gouty arthritis and the gut ecosystem might act as a potential anti-inflammatory target of Simiao decoction.
四妙汤是一种经典的中药方剂,因其在治疗痛风性关节炎方面的安全性和有效性,已被广泛应用了数千年。本研究利用血清促炎细胞因子和肠道生态系统,阐明了四妙汤缓解痛风性关节炎的机制。将四妙汤(4.0、8.0和16.0 g/kg)口服给予痛风性关节炎小鼠,非布司他作为阳性对照。脾脏、肾脏和肝脏指标表明,四妙汤对C57BL/6小鼠痛风性关节炎的治疗是安全的。此外,我们的研究表明,四妙汤可有效降低血清尿酸水平,降低MPO、XOD和ADA活性,并缓解痛风相关症状,如足部肿胀和疼痛。此外,四妙汤还可降低一些特定的血清促炎细胞因子,包括IL-1β、IL-9、IFN-γ、MIP-1α和MIP-1β。然后,我们通过结合网络药理学、ELISA、western blot和illumina测序,系统地研究了四妙汤对肠道生态系统的影响。在痛风性关节炎小鼠模型中,四妙汤可抑制NLRP3炎性小体表达,通过调节TNF-α、Caspase 8和AIFM1蛋白表达减少肠道细胞凋亡,通过调节APOB、LPL、PPARα蛋白表达影响脂质代谢,并恢复肠道微生物群,减少潜在病原体。总体而言,这些发现表明,四妙汤是治疗痛风性关节炎的有效药物,肠道生态系统可能是四妙汤潜在的抗炎靶点。